title: Advances in the treatment of rheumatoid arthritis.
abstract: The intense pursuit of novel therapies in rheumatoid arthritis has provided physicians with an assorted set of biologic drugs to treat patients with moderate to severe disease activity. Nine different biologic therapies are currently available: seven inhibitors of pro-inflammatory cytokines (five targeting tumor necrosis factor [TNF], one interleukin [IL]-1 and one IL-6), as well as a T- and a B-lymphocyte targeting agent. All these drugs have roughly similar efficacy profiles and are approved as first- or second-line therapy in patients who failed to respond to conventional disease-modifying anti-rheumatic drugs (DMARDs) and in most cases for first line use in rheumatoid arthritis as well. Despite the irrefutable clinical and radiological benefits of biologic therapies, there are still low rates of patients achieving stable remission. Therefore, the quest for new and more effective biologic therapies continues and every year new drugs are tested. Simultaneously, optimal use of established agents is being studied in different ways. Recently, the approval of the first small molecule targeting intracellular pathways has opened a new chapter in the treatment of rheumatoid arthritis. Other emerging treatment strategies include the activation of regulatory T cells as well as new cytokine-targeting therapies.
authors.affiliation: Department of Medicine, Unit of Clinical Therapy Research in Inflammatory Diseases (ClinTRID) Karolinska University Hospital, D2:00, 171 76 Stockholm Sweden.
authors.forename: Nancy
authors.initials: N
authors.lastname: Vivar
authors.affiliation: Department of Medicine, Unit of Clinical Therapy Research in Inflammatory Diseases (ClinTRID) Karolinska University Hospital, D2:00, 171 76 Stockholm Sweden.
authors.forename: Ronald F
authors.initials: RF
authors.lastname: Van Vollenhoven